Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052.
Hepatitis C pharmacogenetics: state of the art in 2010.
Afdhal NH,
McHutchison JG,
Zeuzem S,
Mangia A,
Pawlotsky JM,
Murray JS,
Shianna KV,
Tanaka Y,
Thomas DL,
Booth DR,
Goldstein DB;
Pharmacogenetics and Hepatitis C Meeting Participants.
Aerssens J, Afdhal NH, Anderson SM, Amur SG, Birnkrant D, Murray JS, Robertson SM, Struble KA, Whitaker K, Apelian D, Appleman J, Arbeit RD, Berrey MM, Booth DR, Botfield M, George S, Brass C, Brews J, Clark P, McHutchison JG, Naggie S, Patel K, Thompson AJ, Brun SC, Carrington M, Chao S, Rossi SJ, Cloherty G, Coakley EP, Fellay J, Goldstein DB, Shianna KV, Urban TJ, Faruki H, Hopkins S, Hughes N, Kish C, Kreter B, Lee WA, Liang TJ, Thomas E, Lopatin U, Manda V, Scherer R, Van Antwerp W, Mangia A, Mizokami M, Oldach D, Pawlotsky JM, Picchio G, Schulman KA, Subramanian GM, Sulkowski MS, Tanaka Y, Thommes JA, Zeuzem S, Zhu Y.
Source
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. nafdhal@caregroup.harvard.edu
Abstract
In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.
Copyright © 2010 American Association for the Study of Liver Diseases.
- PMID:
- 21254181
- [PubMed - indexed for MEDLINE]
-
Publication Types
MeSH Terms
Substances
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases